Business Context and Reporting Period
This Form 8-K Current Report was filed by Diebold Nixdorf, Inc. on May 5, 2023. The filing addresses two primary corporate events: a notice of non-compliance with NYSE listing standards regarding minimum share price and an extension of a public exchange offer for outstanding senior notes.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, or cash flow data. The only specific financial metric disclosed is the stock price performance triggering the listing notice:
- Share Price Deficiency: The average closing price of Common Shares was less than $1.00 per share over a consecutive 30-trading-day period ending May 4, 2023.
- Debt Instrument: The company is conducting an exchange offer for its 8.50% Senior Notes due 2024.
Material Changes and Events
NYSE Listing Standard Notice (Item 3.01)
On May 5, 2023, the Company received notice from the NYSE that it failed to meet the continued listing standard (Section 802.01C) due to the share price falling below $1.00. The notice has no immediate impact on the listing status, but the Company must notify the NYSE of its intent to cure within 10 business days.
Exchange Offer Extension (Item 8.01)
The Company extended the expiration of its public exchange offer for the 8.50% Senior Notes due 2024. The new expiration time is 5:00 p.m. New York City time on May 19, 2023. All other terms of the offer remain unchanged.
Outlook, Risks, and Management Commentary
Cure Period: The Company has a six-month period from the receipt of the notice to regain compliance with the minimum share price requirement. Compliance can be achieved if the closing share price is at least $1.00 and the 30-day average closing price is at least $1.00 on the last trading day of any calendar month during the cure period.
Operational Impact: Management states that the Listing Standard Notice does not affect business operations or SEC reporting obligations.
Risks: The filing includes standard forward-looking statement disclaimers. Key risks identified include the Company's ability to cure the listing deficiency and the potential for Common Shares to be delisted from the NYSE if compliance is not achieved.
Investor Verification Checklist
- Verify the current trading price of DBD stock to assess progress toward the $1.00 minimum threshold.
- Monitor the Company's formal response to the NYSE regarding its intent to cure the deficiency (due within 10 business days of May 5, 2023).
- Review the terms of the 8.50% Senior Notes due 2024 exchange offer to understand potential capital structure changes.
- Check subsequent filings for updates on the exchange offer results and the status of the NYSE listing compliance.